Related Experiment Videos
Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer
W L Neuman1, M L Wasylyshyn, R Jacoby
1Department of Medicine, University of Chicago, IL 60637.
Abstract:
We examined tissue extracted from 19 gastric, 7 pancreatic, and 23 colorectal carcinoma specimens to determine the comparative incidence of allele loss on chromosomes 5, 17, and 18 and that of KRAS2 point mutations. Chromosome 5 allele loss occurred at the same frequency in all three gastrointestinal tumors (approximately 30%), whereas chromosome 17 and 18 allele losses were seen at a significantly lower frequency in gastric (20%) and pancreatic (0%) malignancies than in colorectal cancer (57%). Point mutations in KRAS2 were seen in 83% of pancreatic and 52% of colon cancers, but not in gastric cancer specimens. In pancreatic tumors, these mutations were always found in the second nucleotide of codon 12. In colorectal cancer, the distribution was more variable, involving the second nucleotide of codon 13 and both the first and second nucleotides of codon 12. These results suggest that inactivation of the adenomatous polyposis coli gene on chromosome 5 may be an initiating step for carcinomas of the stomach and pancreas as well as of the colon, but that the genes involved in tumor progression events may be tissue- or tumor-specific.
Insights
Allele loss on chromosome 5 is common in gastric, pancreatic, and colorectal cancers. However, chromosome 17 and 18 allele losses and KRAS2 mutations are more specific to colorectal and pancreatic tumors, suggesting distinct tumor progression pathways.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastrointestinal cancers, including gastric, pancreatic, and colorectal carcinomas, represent a significant global health burden.
- Understanding the genetic alterations underlying these malignancies is crucial for developing targeted therapies.
- Specific chromosomal regions and gene mutations are implicated in cancer development and progression.
Purpose of the Study:
- To compare the incidence of allele loss on chromosomes 5, 17, and 18.
- To determine the frequency of KRAS2 point mutations across gastric, pancreatic, and colorectal cancer specimens.
- To elucidate potential differences in genetic alterations driving tumor initiation and progression in these distinct gastrointestinal malignancies.
Main Methods:
- Analysis of tissue samples from 19 gastric, 7 pancreatic, and 23 colorectal carcinoma specimens.
- Assessment of allele loss frequencies on chromosomes 5, 17, and 18.
- Detection and characterization of KRAS2 point mutations, including specific codons and nucleotides.
Main Results:
- Chromosome 5 allele loss occurred at a similar frequency (~30%) in all three tumor types.
- Chromosome 17 and 18 allele losses were significantly lower in gastric (20%) and pancreatic (0%) cancers compared to colorectal cancer (57%).
- KRAS2 point mutations were prevalent in pancreatic (83%) and colorectal (52%) cancers but absent in gastric cancer, with distinct mutation site patterns.
Conclusions:
- Inactivation of the adenomatous polyposis coli gene (chromosome 5) may be an early event in the development of gastric, pancreatic, and colorectal carcinomas.
- The observed differences in chromosome 17/18 allele loss and KRAS2 mutations suggest tissue-specific genetic alterations driving tumor progression.
- These findings highlight the heterogeneity of genetic events in gastrointestinal cancer progression, potentially impacting therapeutic strategies.